Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Participants taking tirzepatide lost an average of 15.3% of their body weight after a year, while those on semaglutide lost about 8.3%
Jastreboff AM, Kaplan LM, Frias JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity a phase 2 trial
They wont be part of North 40 (inventory) anymore, Jorgensen says
There can be no assurance that the Funds investment objectives will be achieved
The medications also are gaining expanded approval from regulators and increased health coverage
There were also higher case complexities and more costly technologies (e.g., new inpatient treatments)
US$ 25.51
US$ 28.20
US$ 27.66
US$ 29.85
